A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.
A rare genetic condition, Spinal Muscular Atrophy (SMA) affects one in 7,000 people in India. It mostly affects children and ...
Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...
In the time since the Novartis gene therapy Zolgensma was approved for babies with spinal muscular atrophy, other treatments ...
Apitegromab, a fully human monoclonal antibody, works by selectively binding to the pro- and latent forms of myostatin in order to inhibit myostatin activation.
The high court noted that SMA is a debilitating disease which has no cure, and the only approved drug, Risdiplam, marketed ...
Apitegromab is an investigational treatment aimed at improving motor function for people living with spinal muscular atrophy. Scholar Rock said it has also submitted and received validation for its ...
Speakers from the Muscular Dystrophy Association (MDA) highlighted 75 years of progress in understanding and treating ...
Video: Spinal Muscular Atrophy: When is Surgical Intervention Appropriate? —How does one time surgery for scoliosis in children with pediatric spinal muscular atrophy get a maximum benefit ...
The Delhi High Court on Monday dismissed an interim injunction application filed by Swiss pharmaceutical giant F Hoffmann-La ...
1d
The bench said that public good outweighs the company’s profit as the drug is not available at an affordable price in India.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback